MYC and non-Hodgkin lymphoma: The maximal extent of MCL1 mRNA downregulation in patients with DH-DLBCL and other MYC+ NHL was 49.28% (range, 31%–52.4%) and 44.54% (range, 22.5%–48.2%), respectively (Supplementary Fig. S2A).